Deepinder Goyal, founder of Zomato and the new health tech startup behind Temple, has faced criticism for his high-priced device, which is currently available for pre-orders with a shipping date set for 2027. Despite being an Indian startup, Goyal asserts that Temple is not intended for the Indian market but rather for global consumers, expecting less than 1% of sales to come from India due to its steep price of Rs 85,000. In response to criticism, primarily from doctors, Goyal defended the product's worth and stressed that it is a fitness + AI device, not a medical product. He clarified that Temple does not diagnose or prevent any disease and emphasized that scientific evidence will be available through peer-reviewed research. The device, which adheres to the side of the head with optical sensors tracking brain blood flow signals, has faced skepticism from some doctors like Cyriac Abby Philips over its science and research methodology. Goyal encourages potential buyers to wait for user reviews before making a decision, while assuring that regulatory clearances will be obtained where necessary.